# Efficacy and Safety Study of QAW039 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis.

> **NCT01785602** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 103 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** QAW039
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01785602
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2014-11
- **Final completion:** 2014-11
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2015-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01785602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01785602, "Efficacy and Safety Study of QAW039 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis.". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01785602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*